# US 2021/0010083 A1 · Temporal pediatric sepsis biomarker risk model

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0010083 A1
- Document ID: US20210010083A1
- Status: Published application
- Kind: A1
- Application number: 16/948,556
- Filed: 2020-09-23
- Published: 2021-01-14
- Earliest claimed: 2013-11-25
- Assignees: Children's Hospital Medical Center; University of Cincinnati
- Applicants: Children's Hospital Medical Center; University of Cincinnati
- Inventors: Christopher John Lindsell; Hector R. Wong
- Web page: https://patentgrep.com/patent/US20210010083A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Methods and compositions disclosed herein generally relate to methods of identifying, validating, and measuring clinically relevant, quantifiable biomarkers of diagnostic and therapeutic responses for blood, vascular, cardiac, and respiratory tract dysfunction, particularly as those responses relate to septic shock in pediatric patients. In particular, the invention relates to identifying one or more biomarkers associated with septic shock in pediatric patients, obtaining a sample from a pediatric patient having at least one indication of septic shock, then quantifying from the sample an amount of one or more of said biomarkers, wherein the level of said biomarker correlates with a predicted outcome.

## Claims

### Claim 1

A method of monitoring the therapeutic efficacy of a first treatment administered to a patient with septic shock, and administering to the patient a second treatment, the method comprising:
analyzing a first sample that has been obtained from the patient at a first time point, which is during day 1 of presentation with septic shock and before the first treatment has been administered, to determine a first serum concentration level of each of two biomarkers consisting of C-C chemokine ligand 3 (CCL3) and interleukin-8 (IL8);
analyzing a second sample that has been obtained from the patient at a second time point, which is during day 3 of presentation with septic shock and after the first treatment has been administered to the patient, to determine a second serum concentration level of each of the biomarkers;
determining whether the level of each biomarker is elevated above a cut-off level at each of the first and second time points,
identifying the patient as at high risk for a poor outcome where any one of the following is true:
a) a non-elevated level of CCL3 and an elevated level of IL8 at the first time point, and a highly elevated level of IL8 at the second time point, or
b) a highly elevated level of CCL3 at the first time point, and a non-elevated level of IL8 at the second time point, or
c) an elevated level of CCL3 and a highly elevated level of IL8 at the first time point, and an elevated level of IL8 at the second time point; and
discontinuing administration of the first treatment and administering to the patient identified as at high risk for a poor outcome a second treatment selected from one or more of extracorporeal membrane oxygenation/life support, plasmapheresis, pulmonary artery catheterization, and high volume continuous hemofiltration.

### Claim 2 (depends on 1)

The method of claim 1, further comprising analyzing the second sample for a third biomarker, heat shock protein 70 kDa (HSPA1B) and identifying the patient as at high risk for a poor outcome where the patient has an elevated level of CCL3 and a non-highly elevated level of IL8 at the first time point, and elevated levels of IL8 and HSPA1B at the second time point.

### Claim 3 (depends on 1)

The method of claim 1, further comprising obtaining at least one additional sample(s) from the patient after a treatment has been administered to the patient and analyzing the at least one additional sample for the level of CCL, IL8, or HSPA1B.

### Claim 4 (depends on 3)

The method of claim 3, wherein the at least one additional sample is obtained 12-36 hours after the second time point.

### Claim 5 (depends on 3)

The method of claim 3, wherein the at least one additional sample is obtained within the first 60 hours of presentation with septic shock.

### Claim 6 (depends on 1)

The method of claim 1, wherein
a) an elevated level of CCL3 at the first time point corresponds to a serum CCL3 concentration greater than 130 pg/ml,
b) a highly elevated level of CCL3 at the first time point corresponds to a serum CCL3 concentration greater than 216 pg/ml,
c) an elevated level of IL8 at the first time point corresponds to a serum IL8 concentration greater than 125 pg/ml,
d) a highly elevated level of IL8 at the first time point corresponds to a serum IL8 concentration greater than 436 pg/ml,
e) an elevated level of IL8 at the second time point corresponds to a serum IL8 concentration greater than 33 pg/ml, and
f) a highly elevated level of IL8 at the second time point corresponds to a scrum IL8 concentration greater than 123 pg/ml.

### Claim 7 (depends on 2)

The method of claim 2, wherein an elevated level of HSPA1B at the second time point corresponds to a serum HSPA1B concentration greater than 1.20 μg/ml.

### Claim 8 (depends on 1)

The method of claim 1, wherein the method further comprises receiving one or more patient demographic data and/or clinical characteristics and/or results from other tests or indicia of septic shock.

### Claim 9 (depends on 8)

The method of claim 8, wherein
a) the patient demographic data comprises the age of the patient, or
b) wherein the patient demographic data and/or clinical characteristics and/or results from other tests or indicia of septic shock comprises the septic shock causative organism, the presence or absence of chronic disease, and/or the gender, race, and/or co-morbidities of the patient.

### Claim 10 (depends on 1)

The method of claim 1, wherein the determination of whether the level(s) of the one or more biomarkers are elevated is combined with one or more additional population-based risk scores.

### Claim 11 (depends on 10)

The method of claim 10, wherein the one or more population-based risk scores comprises pediatric risk of mortality (PRISM) and/or pediatric index of mortality (PIM).
